Oruka Therapeutics (ORKA) Competitors $14.80 +0.55 (+3.86%) Closing price 04:00 PM EasternExtended Trading$14.80 +0.00 (+0.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ORKA vs. CNTA, HRMY, ADPT, SRPT, TARS, IMCR, ARQT, SPRY, SDGR, and OCULShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), Tarsus Pharmaceuticals (TARS), Immunocore (IMCR), Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Oruka Therapeutics vs. Its Competitors Centessa Pharmaceuticals Harmony Biosciences Adaptive Biotechnologies Sarepta Therapeutics Tarsus Pharmaceuticals Immunocore Arcutis Biotherapeutics ARS Pharmaceuticals Schrodinger Ocular Therapeutix Centessa Pharmaceuticals (NASDAQ:CNTA) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability. Do institutionals and insiders hold more shares of CNTA or ORKA? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 7.1% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 24.7% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor CNTA or ORKA? In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than Oruka Therapeutics. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 2 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.71 beat Centessa Pharmaceuticals' score of 0.62 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer CNTA or ORKA? Centessa Pharmaceuticals presently has a consensus price target of $27.89, suggesting a potential upside of 78.20%. Oruka Therapeutics has a consensus price target of $40.38, suggesting a potential upside of 172.80%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20 Which has preferable valuation & earnings, CNTA or ORKA? Oruka Therapeutics has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M305.12-$235.76M-$1.81-8.65Oruka TherapeuticsN/AN/A-$83.72M-$4.51-3.28 Which has more volatility & risk, CNTA or ORKA? Centessa Pharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500. Is CNTA or ORKA more profitable? Oruka Therapeutics' return on equity of -25.66% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.22% -29.95% Oruka Therapeutics N/A -25.66%-23.39% SummaryOruka Therapeutics beats Centessa Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$533.53M$2.45B$5.57B$9.31BDividend YieldN/A1.79%4.23%4.03%P/E RatioN/A9.1928.6119.73Price / SalesN/A587.68412.31173.11Price / CashN/A164.3436.0257.96Price / Book1.374.698.235.67Net Income-$83.72M$30.99M$3.23B$257.79M7 Day Performance4.01%0.60%-0.01%0.52%1 Month Performance19.07%7.93%5.61%8.84%1 Year PerformanceN/A-5.48%26.52%14.18% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics2.933 of 5 stars$14.80+3.9%$40.38+172.8%N/A$533.53MN/A0.00N/ANews CoveragePositive NewsCNTACentessa Pharmaceuticals3.1616 of 5 stars$13.62-3.2%$27.89+104.8%+58.1%$1.88B$6.85M-7.52200HRMYHarmony Biosciences4.8362 of 5 stars$32.24+0.2%$53.63+66.3%+2.4%$1.85B$714.73M12.31200News CoveragePositive NewsADPTAdaptive Biotechnologies2.8454 of 5 stars$11.74-0.5%$10.57-10.0%+174.4%$1.79B$178.96M-12.23790SRPTSarepta Therapeutics4.7368 of 5 stars$17.32-5.0%$60.88+251.5%-88.1%$1.79B$1.90B-6.441,372Trending NewsTARSTarsus Pharmaceuticals1.8304 of 5 stars$39.93-3.0%$66.67+67.0%+44.9%$1.73B$182.95M-14.6350News CoveragePositive NewsAnalyst RevisionIMCRImmunocore1.4335 of 5 stars$32.41-1.8%$58.89+81.7%-10.9%$1.66B$310.20M-75.37320ARQTArcutis Biotherapeutics1.2756 of 5 stars$13.39-3.1%$18.80+40.4%+43.0%$1.65B$196.54M-12.88150Insider TradeSPRYARS Pharmaceuticals2.8316 of 5 stars$17.09+3.5%$31.00+81.4%+50.6%$1.62B$97.12M-106.8190News CoverageGap UpSDGRSchrodinger1.7902 of 5 stars$20.63-2.3%$33.25+61.2%-10.2%$1.55B$207.54M-7.84790Positive NewsAnalyst ForecastOCULOcular Therapeutix3.8945 of 5 stars$9.61-0.1%$17.33+80.4%+31.6%$1.53B$63.72M-8.36230 Related Companies and Tools Related Companies CNTA Competitors HRMY Competitors ADPT Competitors SRPT Competitors TARS Competitors IMCR Competitors ARQT Competitors SPRY Competitors SDGR Competitors OCUL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORKA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORKA Stock Alerts